PBYI - Puma Biotechnology, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Los Angeles,
United States
Type: Equity
PBYI price evolution
PBYI
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $84.58 | $81.8 | $60.01 | $61.39 |
| Short term investments | $11.35 | $3.23 | $14.43 | $9.82 |
| Net receivables | $47.84 | $28.97 | $31.29 | $31.16 |
| Inventory | $7.08 | $5.68 | $7.63 | $3.89 |
| Total current assets | $156.19 | $125.35 | $118.55 | $111.75 |
| Long term investments | $2.09 | $2.59 | $2.59 | $2.59 |
| Property, plant & equipment | $8.65 | $9.45 | $10.89 | $11.67 |
| Goodwill & intangible assets | $60.87 | $63.3 | $65.74 | $68.17 |
| Total noncurrent assets | $74.34 | $78.25 | $81.94 | $84.5 |
| Total investments | $13.45 | $5.82 | $17.02 | $12.41 |
| Total assets | $230.53 | $203.6 | $200.49 | $196.26 |
| Current liabilities | ||||
| Accounts payable | $6.89 | $5.06 | $7.79 | $8.59 |
| Deferred revenue | ||||
| Short long term debt | $38.8 | $27.29 | $15.79 | $4.3 |
| Total current liabilities | $99.38 | $67.36 | $60.29 | $48.19 |
| Long term debt | $72.69 | $84.93 | $97.14 | $109.34 |
| Total noncurrent liabilities | $77.7 | $97.5 | $109.81 | $122.22 |
| Total debt | $111.49 | $112.22 | $112.94 | $113.64 |
| Total liabilities | $177.09 | $164.86 | $170.09 | $170.41 |
| Shareholders' equity | ||||
| Retained earnings | -$1345.16 | -$1357.43 | -$1363.23 | -$1365.35 |
| Other shareholder equity | -$0 | -$0 | -$0.01 | |
| Total shareholder equity | $53.44 | $38.74 | $30.4 | $25.85 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $84.58 | $76.2 | $71.98 | $94.14 |
| Short term investments | $11.35 | $4.87 | $18.98 | $8.1 |
| Net receivables | $47.84 | $42.27 | $32.53 | $25.54 |
| Inventory | $7.08 | $4.53 | $7.11 | $3.45 |
| Total current assets | $156.19 | $134.28 | $140.02 | $146.14 |
| Long term investments | $2.09 | $2.59 | $3.31 | $3.31 |
| Property, plant & equipment | $8.65 | $12.51 | $15.77 | $18.89 |
| Goodwill & intangible assets | $60.87 | $70.61 | $66.13 | $74.14 |
| Total noncurrent assets | $74.34 | $87.78 | $86.56 | $98.08 |
| Total investments | $13.45 | $7.46 | $22.29 | $11.41 |
| Total assets | $230.53 | $222.06 | $226.59 | $244.22 |
| Current liabilities | ||||
| Accounts payable | $6.89 | $6.44 | $11.17 | $12.08 |
| Deferred revenue | ||||
| Short long term debt | $38.8 | $4.14 | $3.57 | $17.38 |
| Total current liabilities | $99.38 | $77.48 | $109.59 | $114.25 |
| Long term debt | $72.69 | $98.31 | $113.07 | $103.57 |
| Total noncurrent liabilities | $77.7 | $122.97 | $119.44 | $135.92 |
| Total debt | $111.49 | $114.28 | $116.64 | $120.95 |
| Total liabilities | $177.09 | $200.45 | $229.03 | $250.17 |
| Shareholders' equity | ||||
| Retained earnings | -$1345.16 | -$1366.76 | -$1366.76 | -$1337.63 |
| Other shareholder equity | -$0 | -$0 | ||
| Total shareholder equity | $53.44 | $21.61 | -$2.45 | -$5.95 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $72.18 | $56.12 | $54.57 | $52.77 |
| Cost of revenue | $24.32 | $13.28 | $11.86 | $13.22 |
| Gross Profit | $47.85 | $42.83 | $42.71 | $39.56 |
| Operating activities | ||||
| Research & development | $12.87 | $11.45 | $13.36 | $12.71 |
| Selling, general & administrative | $20.18 | $22.8 | $24.46 | $22.49 |
| Total operating expenses | $33.06 | $34.25 | $37.82 | $35.19 |
| Operating income | $14.8 | $8.59 | $4.89 | $4.37 |
| Income from continuing operations | ||||
| EBIT | $16.16 | $9.35 | $5.64 | $4.86 |
| Income tax expense | $0.54 | $0.21 | $0.19 | $0.15 |
| Interest expense | $3.35 | $3.34 | $3.33 | $3.31 |
| Net income | ||||
| Net income | $12.27 | $5.8 | $2.13 | $1.4 |
| Income (for common shares) | $12.27 | $5.8 | $2.13 | $1.4 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $235.64 | $228.03 | $253.16 | $225.11 |
| Cost of revenue | $62.68 | $55.09 | $63.7 | $39.37 |
| Gross Profit | $172.96 | $172.94 | $189.45 | $185.74 |
| Operating activities | ||||
| Research & development | $50.38 | $52.24 | $71.87 | $97.65 |
| Selling, general & administrative | $89.93 | $89.98 | $116.29 | $118.49 |
| Total operating expenses | $140.31 | $149.22 | $188.16 | $216.14 |
| Operating income | $32.64 | $23.72 | $1.29 | -$30.4 |
| Income from continuing operations | ||||
| EBIT | $36 | $12.05 | -$15.99 | -$45.74 |
| Income tax expense | $1.08 | $0.46 | $0.32 | $0.21 |
| Interest expense | $13.33 | $11.59 | $12.81 | $14.05 |
| Net income | ||||
| Net income | $21.59 | $0 | -$29.13 | -$59.99 |
| Income (for common shares) | $21.59 | $0 | -$29.13 | -$59.99 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $12.27 | $5.8 | $2.13 | $1.4 |
| Operating activities | ||||
| Depreciation | $2.89 | $2.88 | $2.88 | $2.88 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.43 | $2.54 | $2.43 | $2.84 |
| Total cash flows from operations | $10.46 | $10.62 | $3.3 | $2.64 |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$0.03 | -$0.07 | |
| Investments | -$8.13 | $11.21 | -$4.62 | -$4.95 |
| Total cash flows from investing | -$8.17 | $11.18 | -$4.68 | -$17.45 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | ||||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $2.29 | $21.79 | -$1.39 | -$14.81 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $21.59 | $0 | -$29.13 | -$59.99 |
| Operating activities | ||||
| Depreciation | $11.52 | $8.92 | $10.6 | $10.03 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $10.25 | $11.83 | $32.63 | $36.58 |
| Total cash flows from operations | $27.01 | -$15.83 | $20.65 | $0.77 |
| Investing activities | ||||
| Capital expenditures | -$0.14 | -$0.05 | ||
| Investments | -$6.49 | $14.1 | -$10.88 | $43.45 |
| Total cash flows from investing | -$19.13 | $7.1 | -$10.88 | $23.4 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $12.22 | $0.07 | ||
| Net borrowings | -$11.93 | |||
| Total cash flows from financing | $12.22 | -$31.93 | $0.07 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $7.88 | $3.5 | -$22.16 | $24.24 |
News
Fundamentals
| Market cap | $232.52M |
|---|---|
| Enterprise value | $259.42M |
| Shares outstanding | 47.65M |
| Revenue | $235.64M |
|---|---|
| EBITDA | $47.52M |
| EBIT | $36.00M |
| Net Income | $21.59M |
| Revenue Q/Q | 9.90% |
| Revenue Y/Y | 3.34% |
| P/E ratio | 10.77 |
|---|---|
| EV/Sales | 1.10 |
| EV/EBITDA | 5.46 |
| EV/EBIT | 7.21 |
| P/S ratio | 0.99 |
| P/B ratio | 4.35 |
| Book/Share | 1.12 |
| Cash/Share | 1.78 |
| EPS | $0.45 |
|---|---|
| ROA | 10.39% |
| ROE | 58.19% |
| Debt/Equity | 3.31 |
|---|---|
| Net debt/EBITDA | 1.95 |
| Current ratio | 1.57 |
| Quick ratio | 1.50 |